HAVCR2 and leukemia: Anti–TIM-3 treatment also reduced the leukemia burden in FLT3-ITD MLL-PTD–driven AML, as evidenced by decreased AML cell frequency in the BM at day 23 after allo-HCT (Figure 1L).